SPRUCE BIOSCIENCES Business Summary

Spruce Biosciences, Inc. (SPRB) is a late-stage biopharmaceutical company that operates through a research-and-development-heavy business model, primarily generating revenue through strategic licensing agreements and clinical collaborations, such as its precision psychiatry partnership with HMNC Brain Health. The company’s primary business segments are focused on rare endocrine and neurodegenerative disorders, with its lead asset, tralesinidase alfa (TA-ERT), currently being prepared for a Biologics License Application (BLA) submission in Q4 2026 for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). Following a strategic pivot from its initial focus on Congenital Adrenal Hyperplasia (CAH) due to mid-stage clinical setbacks, Spruce now positions itself as a specialist in enzyme replacement therapies and HPA axis modulation. It competes directly with rare disease and endocrine-focused firms such as Neurocrine Biosciences, Crinetics Pharmaceuticals, and Ascendis Pharma, distinguishing itself through its focus on surrogate endpoints like CSF HS-NRE for accelerated FDA approval pathways. Founded by Alexis Howerton, Ph.D., the company is led by Chief Executive Officer Javier Szwarcberg, M.D., M.P.H., whose pedigree includes senior leadership roles at BioMarin and Ultragenyx. The executive team is further bolstered by President and CFO Samir Gharib, an experienced biopharma financier, and Chief Medical Officer Kirk Ways, M.D., Ph.D. Recent 2026 leadership expansions include the appointments of Daven Mody as SVP of Regulatory and Quality and Bruno Gagnon as SVP of Clinical Development Operations to steer the TA-ERT regulatory filing. Spruce is supported by a high-profile board chaired by Michael Grey and maintains significant institutional backing from notable investors including The Carlyle Group, Abingworth, Novo Holdings, and Omega Funds.